ライフサイエンスコーパス: clinical benefit

1 mbination of efficacy and safety events (net clinical benefit).

2 o diminish pathologies resulting from it for clinical benefit.

3 ntigens and have thus far resulted in little clinical benefit.

4 ated, with 31% showing objective evidence of clinical benefit.

5 real-life, lead to absence of long-term AIT clinical benefit.

6 after cure of hepatitis C translates into a clinical benefit.

7 search is needed to understand the long-term clinical benefit.

8 e therapy and pancreatectomy for PDAC was of clinical benefit.

9 200 mg) until disease progression or loss of clinical benefit.

10 nly a subset of patients demonstrate durable clinical benefit.

11 tent or novel class of antagonist could have clinical benefit.

12 n patients with AAV, thus offering potential clinical benefit.

13 ovement that is reasonably likely to predict clinical benefit.

14 ystemic tumor response with potential future clinical benefit.

15 these exosomes could be tailored to maximize clinical benefit.

16 response signature) that was associated with clinical benefit.

17 s overwhelming scientific progress into real clinical benefit.

18 bleeding complications continue to undermine clinical benefit.

19 pain, for which there is little evidence of clinical benefit.

20 te shortcomings in the evidence about actual clinical benefit.

21 Yet, only a subset of patients derive clinical benefit.

22 esponses, enhance tumor killing, and provide clinical benefit.

23 RAFi) is the primary cause for their limited clinical benefit.

24 es faced in translating in vitro findings to clinical benefit.

25 to ensure that patients can achieve maximal clinical benefit.

26 tation; for severe bleeding; and for the net clinical benefit.

27 be used to target those most likely to gain clinical benefit.

28 y, hopefully, improve the ability to predict clinical benefit.

29 he 30-mg once-daily dose showed the greatest clinical benefit.

30 either do not respond or do not have durable clinical benefit.

31 who had no therapeutic options of potential clinical benefit.

32 nd major bleeding, which constituted the net clinical benefit.

33 loping approaches to modulate Treg cells for clinical benefit.

34 antly higher healthcare cost without a clear clinical benefit.

35 esponse so they can be leveraged for maximum clinical benefit.

36 lecule S6K1/MDM2 antagonists that could have clinical benefit.

37 lly reveal avenues that can be exploited for clinical benefit.

38 t mitochondrial regulation of cell death for clinical benefit.

39 s with plexiform neurofibromas and to assess clinical benefit.

40 e most significant biomarker associated with clinical-benefit.

41 y and to mixed results in terms of long-term clinical benefits.

42 rtunistic infections that might outweigh any clinical benefits.

43 ng therapeutics are associated with variable clinical benefits.

44 factor inhibition that may further modulate clinical benefits.

45 rs), treatment with ULT conferred consistent clinical benefits.

46 treatment seems to be necessary to maintain clinical benefits.

47 l changes in the GFR slope will translate to clinical benefits.

48 ot associated with statistically significant clinical benefits.

49 -10-based therapies have shown only marginal clinical benefits.

50 ents were limited to drugs that have delayed clinical benefits.

51 improve patient stratification and maximize clinical benefits.

52 that classify patients most likely to derive clinical benefits.

53 not always provide patients with significant clinical benefits.

54 Significantly more patients experienced clinical benefit 1 with mepolizumab versus placebo in th

55 plus OGC dose of 4 mg/d or less (remission 1/clinical benefit 1) or 7.5 mg/d or less (remission 2/cli

56 cebo, 78% versus 32% of patients experienced clinical benefit 1, and 87% versus 53% of patients exper

57 , and 87% versus 53% of patients experienced clinical benefit 2 (both P < .001).

58 benefit 1) or 7.5 mg/d or less (remission 2/clinical benefit 2).

59 Ticagrelor improved net clinical benefit: 519/5558 (9.3%) versus 617/5596 (11.0%

60 nts with cancer resistant to AI alone showed clinical benefit (6 or more months without progression)

61 lial growth factor A (VEGFA) has had limited clinical benefits(7,8).

62 or hydroxchloroquine are unlikely to provide clinical benefit against COVID-19.

63 le ERBB inhibitor lapatinib led to prolonged clinical benefit and a lasting radiographic and metaboli

64 S Interventions (ATN) data, we projected the clinical benefit and cost-effectiveness of frequent HIV

65 ted States, baseline genotype offers minimal clinical benefit and is not cost-effective.

66 The objective of the study was to assess the clinical benefit and patient-reported outcomes in patien

67 rategy to inhibit mitochondrial transfer for clinical benefit and scientifically expands the understa

68 bition in early acute SIV infection provides clinical benefit and suggest a rationale for testing KMO

69 We aimed to assess the clinical benefits and cost-effectiveness of incorporatin

70 There was no direct evidence for the clinical benefits and harms of HBV screening vs no scree

71 d adults there was no direct evidence on the clinical benefits and harms of screening for HIV infecti

72 oietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after.

73 However, the mechanisms underlying this clinical benefit are unknown and improved understanding

74 MPA exposure is successfully controlled and clinical benefits are seen.

75 transplantation (allo-HSCT) recipients, its clinical benefits are still uncertain.

76 of these patients and was associated with a clinical benefit, as it prevented hepatic decompensation

77 and need for mechanical ventilation, showing clinical benefit associated with early treatment.

78 ngs provide new information about short-term clinical benefits associated with loop diuretic use in H

79 ial in North American ICUs assessing the net clinical benefits associated with more frequent screenin

80 Potential reasons for not proving clinical benefit at 40 weeks are discussed.

81 ng 26 patients who were experiencing ongoing clinical benefit at data cut-off.

82 survival (p = 0.0057) and predicted 6-month clinical benefit (AUROC = 0.83) in NSCLC.

83 afamidis is projected to produce substantial clinical benefit but would greatly exceed conventional c

84 seen in tumor or blood in 5/5 patients with clinical benefit, but only in one non-responder.

85 Enzalutamide showed a clinical benefit by delaying pain progression, symptom w

86 led trial, we found widespread moderation of clinical benefits by brain activity during regulation of

87 current mechanistic knowledge and potential clinical benefits, combination therapies of (223)Ra with

88 tors should be balanced with their favorable clinical benefits compared with tamoxifen.

89 All alternative strategies improved clinical benefits compared with the EVAR-1 trial.

90 e and during nivolumab therapy revealed that clinical benefits correlate with reduced expression of S

91 tions (CEPAC)-Pediatric model to examine the clinical benefits, costs, and cost-effectiveness of repl

92 identify which patients will achieve durable clinical benefit (DCB).

93 Clinical benefit, defined as a minimal response or bette

94 (n = 11) had a significantly higher rate of clinical benefit, defined as stable disease lasting >=6

95 Here we show an overall rate of clinical benefit-defined as complete or partial response

96 Early samples from patients with durable clinical benefit demonstrated overexpression of T cell r

97 quality of life and function with sustained clinical benefit depending on symptoms distribution.

98 nce must be considered in the context of the clinical benefit derived from a medically indicated CT a

99 rolling MRSA-related VAP infections; however clinical benefit does not always correlate with antimicr

100 t of DPYD-guided toxicity management and the clinical benefit expressed as quality adjusted life year

101 dividuals at high risk for bleeding, the net clinical benefit favors the use of intensified long-term

102 fective vaccine formulation toward a desired clinical benefit for a clinical vaccine to maximize prot

103 ass II potentiators identified here may have clinical benefit for CF caused by mutations in the NBD2

104 y designed therapy that provides significant clinical benefit for human epidermal growth factor recep

105 yndrome and provides preliminary evidence of clinical benefit for patients on long-term therapy.

106 ntravenous immunoglobulin (hIVIG) might have clinical benefit for patients with influenza infection,

107 ent efforts to translate this knowledge into clinical benefit for patients.

108 herapies and immunotherapies yielded limited clinical benefits for pancreatic cancer patients.

109 -b) or soft tissue augmentation (PhMT-s) has clinical benefits for patients undergoing orthodontic tr

110 cent strides will translate into significant clinical benefits for patients with these disorders.

111 se new insights about glioma metabolism into clinical benefits for patients.

112 digm whereby preliminary measurements of the clinical benefit from a novel treatment can be obtained

113 of AF ablation in patient subgroups in whom clinical benefit from ablation varies, and potential pla

114 lasma on patients with COVID-19 suggest some clinical benefit from early administration and modest im

115 negative metastatic breast cancer with prior clinical benefit from endocrine therapy but later progre

116 y and molecular determinants associated with clinical benefit from ICI therapy.

117 mutational load who experienced only limited clinical benefit from immunotherapy.

118 Patients achieved clinical benefit from maintenance treatment with nirapar

119 eurofibromas had durable tumor shrinkage and clinical benefit from selumetinib.

120 nts with stage III melanoma who might derive clinical benefit from targeted therapy.

121 nts with low type 2 inflammation derive less clinical benefit from therapies targeting type 2 cytokin

122 However, not all patients achieve long-term clinical benefits from immunotherapy as a standalone tre

123 In addition, long-lasting clinical benefits from single-agent therapies rarely occ

124 eting this process could provide significant clinical benefits; however, the development of anti-adhe

125 Sorafenib leads to clinical benefit in a subgroup of patients, whereas all

126 Immunotherapy results in remarkable clinical benefit in a subset of cancer patients by activ

127 ckpoint inhibitors targeting PD-1 have shown clinical benefit in adults with cancer, but data on thes

128 onthly treatment costs for solid tumours and clinical benefit in all assessed countries, using the ES

129 shows that influenza vaccination may have a clinical benefit in allo-HSCT recipients with virologica

130 tumours, and has been associated with marked clinical benefit in cancer patients.

131 unately, candidate drugs have failed to show clinical benefit in established, early, or prodromal dis

132 hile crenolanib monotherapy has demonstrated clinical benefit in heavily pretreated relapsed/refracto

133 hibitor (MEKi) trametinib has failed to show clinical benefit in KRAS-mutant colorectal cancer.

134 asing pro-inflammatory signaling may provide clinical benefit in MDD.

135 n receptor (AR) antagonist, has demonstrated clinical benefit in men with prostate cancer.

136 ine could be repurposed to offer substantial clinical benefit in MS.

137 M2 channel antagonist with the potential for clinical benefit in neurological diseases.

138 e autoimmune diseases but has failed to show clinical benefit in other autoimmune conditions.

139 and associated with antitumour responses and clinical benefit in patients with advanced solid tumours

140 othened (SMO) inhibitors have failed to show clinical benefit in patients with cancers displaying SHH

141 ell therapy should be evaluated for possible clinical benefit in patients with common epithelial canc

142 mab was safe and showed activity and durable clinical benefit in patients with PD-L1-positive, trastu

143 itor simtuzumab for 96 weeks did not provide clinical benefit in patients with PSC.

144 gen receptor (CAR) T cells have demonstrated clinical benefit in patients with relapsed/refractory (R

145 efforts aimed at evaluating a product's net clinical benefit in randomised trials compared with curr

146 sivir initiated early during infection had a clinical benefit in rhesus macaques infected with SARS-C

147 virtually all high-risk cancers, leading to clinical benefit in some patients.

148 n metastases, adjuvant WBRT does not provide clinical benefit in terms of distant intracranial contro

149 non-randomised studies for the evaluation of clinical benefit in the post-marketing period should be

150 genesis, atezolizumab + bevacizumab improves clinical benefit in tumors with high T-effector and/or c

151 danib in non-small cell lung cancer reported clinical benefits in adenocarcinoma (ADC) but not squamo

152 already demonstrated definitive evidence of clinical benefits in cancer and infectious disease.

153 No specific therapies have shown any clinical benefits in patients with asthma that is associ

154 checkpoint blockers have yielded significant clinical benefits in patients with different malignancie

155 IL-17 antagonists induce impressive clinical benefits in psoriasis, but it is unknown to wha

156 elevant chemokine pathway might in fact have clinical benefits in rheumatic diseases.

157 Subcutaneous sarilumab may provide clinical benefits in the management of NIU of the poster

158 ons are additionally found to associate with clinical-benefit in the low-TMB setting.

159 hasize the importance of considering the net clinical benefit including ischemic and bleeding events.

160 19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, red

161 pies that can modify risk factors and confer clinical benefit is available; however, we face consider

162 However, their clinical benefit is currently limited, as only a fractio

163 One potential mechanism of this clinical benefit is from the depletion of pathogenic imm

164 f anxiolytic pharmacotherapy; however, their clinical benefit is limited by side effects and addictiv

165 interventions (TTVI) are promising, but the clinical benefit is unknown.

166 Cancer drugs with low or uncertain clinical benefit might be prioritised for price negotiat

167 lation, ticagrelor provided a favourable net clinical benefit (more than in patients without history

168 Analysis of net clinical benefit (NCB) is of key clinical relevance and

169 F) patients >=75 years, evidence for the net clinical benefit (NCB) of anticoagulant in older adults

170 oints, postauthorisation measures to confirm clinical benefit need to be imposed by the regulator on

171 a neoadjuvant setting is consistent with the clinical benefit observed in hormone receptor-positive,

172 mine the cellular and molecular basis of the clinical benefit observed under rapamycin treatment in 6

173 onal functioning improvements complement the clinical benefits observed with D-VTd versus VTd, and su

174 Our results align with ALEX, confirming the clinical benefit of 600 mg of alectinib twice per day as

175 - reported outcomes (PROs), to determine net clinical benefit of a treatment strategy is needed becau

176 This study sought to determine the clinical benefit of adding alirocumab to statins in ACS

177 unmet need for predictive biomarkers of the clinical benefit of antiangiogenic drugs.

178 aimed to assess the association between the clinical benefit of approved cancer drugs based on these

179 These results demonstrate that the clinical benefit of B(regs) is associated with normaliza

180 The clinical benefit of cell-depleting therapies targeting C

181 we present all available data demonstrating clinical benefit of concurrent dual blockade of the AR R

182 The clinical benefit of CTLA-4 blockade on T cells is known,

183 CASSIOPEIA is the first study showing the clinical benefit of daratumumab plus standard of care in

184 In addition, we show evidence of clinical benefit of deoxynucleoside treatment, especiall

185 The present study showed a transient clinical benefit of DJBL, which was only apparent at 1 y

186 Here, we confirm the clinical benefit of galactose supplementation in PGM1-CD

187 ical parameters that could explain sustained clinical benefit of grass tablet sublingual immunotherap

188 The clinical benefit of hIVIG for patients with influenza B

189 The potential utility and clinical benefit of hybrid operating theaters are increa

190 The clinical benefit of LDL cholesterol lowering treatment i

191 sing Anticoagulation Strategies) trial found clinical benefit of low-dose rivaroxaban plus aspirin, b

192 Therefore, the clinical benefit of lowering triglyceride and LDL-C leve

193 We sought to investigate post hoc the clinical benefit of mepolizumab in patients with EGPA us

194 As a result, the clinical benefit of multiple doses of pegasparaginase wi

195 lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other ma

196 r extended follow-up to inform the long-term clinical benefit of nivolumab plus ipilimumab versus sun

197 kemic efficacy of activated NK cells and the clinical benefit of NK cell-activating immunotherapy.

198 analysis that indicated a low probability of clinical benefit of omega-3 CA vs the corn oil comparato

199 nities for exploiting these findings for the clinical benefit of patients with cohesin-mutant cancers

200 es that employ autophagic mechanisms for the clinical benefit of patients with GBM.

201 The clinical benefit of PCSK9 inhibitors seen in these trial

202 gy against KRAS-mutant NSCLC and propose the clinical benefit of PIERCE1.

203 Despite the clinical benefit of propranolol therapy in hemangioma, t

204 Despite the promising clinical benefit of targeted and immune checkpoint block

205 Despite substantial clinical benefit of targeted and immune checkpoint block

206 This study shows the clinical benefit of targeting IDH1 mutations in advanced

207 of, emotional conflict as a moderator of the clinical benefit of the antidepressant sertraline versus

208 We aimed to evaluate the clinical benefit of weekly selinexor, bortezomib, and de

209 There is ongoing debate on the clinical benefits of antibiotic prophylaxis for reducing

210 These results support the possible clinical benefits of ART in this population.

211 47 000 patients called into question the net clinical benefits of aspirin in primary prevention for 3

212 The clinical benefits of autogenous soft tissue grafts are c

213 In univariate sensitivity analysis, clinical benefits of baseline genotype never exceeded 5

214 egy to overcome T cell exclusion and improve clinical benefits of cancer immunotherapy.

215 There is limited evidence on the long-term clinical benefits of catheter ablation in patients with

216 Despite the clinical benefits of CT imaging, concerns remain regardi

217 Clinical benefits of cytokine blockade in ileal Crohn's

218 his work, we hypothesized that the long-term clinical benefits of DBS are, at least in part, due to a

219 significance in fibrotic cardiac remodeling, clinical benefits of global inhibition of TGF (transform

220 Future RCTs that focus on the potential clinical benefits of HIIT are encouraged given the preva

221 tabolism ultimately led to demonstrating the clinical benefits of lipid lowering.

222 In addition, evidence of the potential clinical benefits of metastasis-directed therapy with io

223 re clinical trials are needed to warrant the clinical benefits of modifying soft tissue phenotype aro

224 hase III study (NCT02000622) established the clinical benefits of olaparib tablet monotherapy (300 mg

225 ciency virus (HIV)-infected persons, but the clinical benefits of smoking cessation are unknown.

226 However, the clinical benefits of such therapies are confounded by tr

227 (CML) is the model cancer, demonstrating the clinical benefits of targeted therapy and the power of m

228 Scarce data exist on the use and potential clinical benefits of the transradial approach as seconda

229 through CMA and AA pathways reliably predict clinical benefits of therapy has not been studied system

230 with MMP inhibitors have failed to yield any clinical benefits of these inhibitors.

231 e being developed to increase and expand the clinical benefits of these treatments in patients with d

232 cohorts that makes it difficult to show the clinical benefits of vaccination, the subsequent need to

233 ope over 3 years or chronic slope predicts a clinical benefit on CKD progress with at least 96% proba

234 esting to demonstrate ICS responsiveness and clinical benefit on electronically monitored treatment w

235 ous opioid system would be expected to yield clinical benefits qualitatively different from conventio

236 [95% CI, 2.8-3.7]; P < .001), and increased clinical benefit rate (80.7% vs 56.7%; P < .001) vs TMB

237 Objective response was 4% and clinical benefit rate (CR + PR + SD > 6 m) was 19%.

238 essed locally; the duration of response; the clinical benefit rate (defined as a complete or partial

239 d by the treating physician in the EHR), and clinical benefit rate (fraction of patients with stable

240 Secondary endpoints included clinical benefit rate and progression-free survival (PFS

241 hotrexate was determined on the basis of the clinical benefit rate at 2 months and circulating endoth

242 of 31% (14 of 45 patients; 95% CI 18-47) and clinical benefit rate of 49% (22 of 45; 34-64) in the al

243 ite instable tumours who received nivolumab (clinical benefit rate of 63%), and a cohort of patients

244 as 8% (one of 13 patients; 0.2-36.0) and the clinical benefit rate was 23% (three of 13; 5-54).

245 The clinical benefit rate was 45.4%.

246 ve was to evaluate overall response rate and clinical benefit rate.

247 onse rate (ORR), duration of response (DOR), clinical-benefit rate, biomarkers, and safety.

248 nd negatively associated with higher durable clinical benefit, reduced hyperprogression, and longer P

249 ver, the immunological mechanisms underlying clinical benefit remain only partially understood.

250 ically altered with ATG induction, long-term clinical benefits remain unclear in pediatric patients.

251 The net clinical benefit remains favorable for most patients tre

252 Sirolimus induced clinical benefit responses in all three patients with du

253 ramework (ASCO-VF) and the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS).

254 an Society for Medical Oncology Magnitude of Clinical Benefit Scale, the American Society of Clinical

255 treatment-naive tumors will provide limited clinical benefit since recurrent metastatic MBs are high

256 vailable CFTR modulators provide only modest clinical benefits, so alternative therapeutic targets ar

257 Vandetanib demonstrated clinical benefit-specifically, increased PFS-in patients

258 bone grafting together with CAOT may provide clinical benefits such as modifying periodontal phenotyp

259 easingly recognized as offering considerable clinical benefit, such as increased antitumour effects a

260 8.7 weeks earlier and was more predictive of clinical benefit than CT imaging.

261 most severe patients and showed the greatest clinical benefit, than in the adult patients.

262 could help identify therapies providing high clinical benefit that should be made rapidly available a

263 lation to the maximum tolerated dose confers clinical benefits that outweigh treatment-related toxic

264 g/kg every 3 weeks was not outweighed by any clinical benefit, the recommended phase 2 dose was set t

265 ic targets whose down-regulation may provide clinical benefit to patients with melanoma.

266 , inhibition of this pathway has provided no clinical benefit to patients with PDA(6).

267 eadth of immune responses that might achieve clinical benefit to treat and prevent MSI tumors.

268 Chemotherapy offers long-term clinical benefits to many patients with advanced cancer.

269 There are no apparent clinical benefits to using liposomal bupivacaine transve

270 mutations are significantly associated with clinical-benefit to checkpoint inhibitor (CPI) therapy (

271 Limited clinical benefit underpins the need for improved underst

272 ugs indicated for solid tumours, we assessed clinical benefit using ASCO-VF and ESMO-MCBS.

273 ere performed to estimate the probability of clinical benefit using Bayesian regression models (an op

274 ting subsequent therapy and provided lasting clinical benefits versus placebo in all three analysis c

275 on between a decrease in tumor perfusion and clinical benefit warrants further investigation.

276 The overall median duration of clinical benefit was 9 months (95% confidence interval o

277 When a comprehensive definition of clinical benefit was applied to data from a randomized c

278 Clinical benefit was assessed in all patients and among

279 Clinical benefit was defined post hoc as follows: remiss

280 up of 30.6 months (IQR 27.2-34.2), continued clinical benefit was observed with pembrolizumab plus ax

281 ke was feasible and most likely safe, but no clinical benefit was seen at 90 days.

282 Although no obvious clinical benefit was substantiated following salvage sur

283 ting parasite rhythms could be exploited for clinical benefit; we propose an interdisciplinary effort

284 The clinical benefits were associated with reduced skin reac

285 Clinical benefits were lost 6 months after withdrawal.Co

286 d non-small-cell lung cancer and also showed clinical benefit when combined with chemotherapy as firs

287 hibitors, most of these same patients report clinical benefit when desensitized to aspirin and mainta

288 o HLA-C*06:02 status could offer substantial clinical benefit when selecting treatments for severe ps

289 isome safety signals and suggested potential clinical benefit, which requires further assessment in a

290 Our findings suggest that a clinical benefit with durvalumab can be attained without

291 g subsets of patients who may derive greater clinical benefit with ezetimibe is unknown.

292 examine the risk of recurrent CV events and clinical benefit with ezetimibe.

293 of glucocorticoids have been shown to confer clinical benefit with respect to osteoarthritis of the k

294 d in routine clinical practice and determine clinical benefit with routine prospective monitoring.

295 Our findings suggest that to provide clinical benefit with the least effect on growth, the nu

296 rovided apparently divergent results about a clinical benefit with the use of >1 arterial conduit.

297 ture studies should aim to confirm the large clinical benefits with sodium glucose transporter-2 inhi

298 ty-three percent of patients had significant clinical benefit, with a 30% progression-free survival o

299 d 12 h postinoculation also provided a clear clinical benefit, with a reduction in clinical signs, re

300 all short of showing significant survival or clinical benefit, with the complex glioma heterogeneity